

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Lal and Owen

**Patent No.** 7,425,611

**Issued:** September 16, 2008

**Application No.** 10/550,651

**Filed:** September 26, 2005

**Confirmation No.** 8346

**For:** IMMUNOGENIC HIV-1 MULTI-CLADE,  
MULTIVALENT CONSTRUCTS AND  
METHODS OF THEIR USE

**Examiner:** Nicole Kinsey White

**Art Unit:** 1648

**Attorney Reference No.** 6395-67675-06

**FILED VIA EFS**

FILED VIA ELECTRONIC FILING SYSTEM  
COMMISSIONER FOR PATENTS

## REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

In the Specification:

In column 1, line 9, "2192)" should read --21(2)--.

In column 1, lines 10-11, "60/458,990" should read --60/458,880--.

In column 3, line 1, "123" should read --β2--.

In column 6, lines 1-2, "of representative" should read --of a representative--.

In column 9, line 38, "between to distinct" should read --between two distinct--.

In column 14, line 57, "cells'" should read --cell's--.

In column 18, line 55, "HV-1 genome" should read --HIV-1 genome--.

In column 33, line 25, "nef Representative" should read --nef. Representative--.

In column 36, line 25, A<sup>01</sup>" should read --A\*01--.

Provided herewith is the fee of \$100.00 pursuant to 37 C.F.R. 1.20(a).

The preceding corrections remedy mistakes of a typographical nature and/or minor character. A Certificate of Correction is enclosed to make formal notice of the errors in the referenced patent.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By \_\_\_\_\_ /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630

cc: Docketing

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,425,611

DATED : September 16, 2008

INVENTOR(S) : Lal and Owen

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

In column 1, line 9, "2192)" should read --21(2)--.

In column 1, lines 10-11, "60/458,990" should read --60/458,880--.

In column 3, line 1, "123" should read --β2--.

In column 6, lines 1-2, "of representative" should read --of a representative--.

In column 9, line 38, "between to distinct" should read --between two distinct--.

In column 14, line 57, "cells'" should read --cell's--.

In column 18, line 55, "HV-1 genome" should read --HIV-1 genome--.

In column 33, line 25, "nef Representative" should read --nef. Representative --.

In column 36, line 25, A<sup>b</sup>01" should read --A<sup>a</sup>01--.

MAILING ADDRESS OF SENDER:  
Klarquist Sparkman, LLP  
One World Trade Center, Suite 1600  
121 SW Salmon Street  
Portland, Oregon 97204

PATENT NO. 7,425,611  
No. of add'l copies \_\_\_\_\_  
(@ .30 per page)